Skip to main content
Top
Published in: Journal of Cancer Research and Clinical Oncology 12/2008

01-12-2008 | Original Paper

Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma

Authors: Yasuo Awakura, Eijiro Nakamura, Takeshi Takahashi, Hirokazu Kotani, Yoshiki Mikami, Tadashi Kadowaki, Akira Myoumoto, Hideo Akiyama, Noriyuki Ito, Toshiyuki Kamoto, Toshiaki Manabe, Hitoshi Nobumasa, Gozoh Tsujimoto, Osamu Ogawa

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2008

Login to get access

Abstract

Purpose

Renal cell carcinoma (RCC) is characterized by a variable and unpredictable clinical course. Thus, accurate prediction of the prognosis is important in clinical settings. We conducted microarray-based study to identify a novel prognostic marker in conventional RCC.

Patients and methods

The present study included the patients surgically treated at Kyoto University Hospital. Gene expression profiling of 39 samples was carried out to select candidate prognostic markers. Quantitative real-time PCR of 65 samples confirmed the microarray experiment results. Finally, we evaluated the significance of potential markers at their protein expression level by immunohistochemically analyzing 230 conventional RCC patients.

Results

Using expression profiling analysis, we identified 14 candidate genes whose expression levels predicted unfavorable disease-specific survival. Next, we examined the expression levels of nine candidate genes by quantitative real-time PCR and selected CUB-domain containing protein 1 (CDCP1) for further immunohistochemical analysis. Positive staining for CDCP1 inversely correlated with disease-specific and recurrence-free survivals. In multivariate analysis including clinical/pathological factors, CDCP1 staining was a significant predictor of disease-specific and recurrence-free survivals.

Conclusions

We identified CDCP1 as a potential prognostic marker for conventional RCC. Further studies might be required to confirm the prognostic value of CDCP1 and to understand its function in RCC progression.
Appendix
Available only for authorised users
Literature
go back to reference Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM (2005) Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 24:5333–5343PubMedCrossRef Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM (2005) Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 24:5333–5343PubMedCrossRef
go back to reference Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG (2002) Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11:2489–2498PubMedCrossRef Bodmer D, van den Hurk W, van Groningen JJ, Eleveld MJ, Martens GJ, Weterman MA, van Kessel AG (2002) Understanding familial and non-familial renal cell cancer. Hum Mol Genet 11:2489–2498PubMedCrossRef
go back to reference Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR (2002) Post-analysis follow-up and validation of microarray experiments. Nat Genet 32(Suppl):509–514PubMedCrossRef Chuaqui RF, Bonner RF, Best CJ, Gillespie JW, Flaig MJ, Hewitt SM, Phillips JL, Krizman DB, Tangrea MA, Ahram M, Linehan WM, Knezevic V, Emmert-Buck MR (2002) Post-analysis follow-up and validation of microarray experiments. Nat Genet 32(Suppl):509–514PubMedCrossRef
go back to reference Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338:1265–1271PubMedCrossRef Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 338:1265–1271PubMedCrossRef
go back to reference Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22:1783–1794PubMedCrossRef Hooper JD, Zijlstra A, Aimes RT, Liang H, Claassen GF, Tarin D, Testa JE, Quigley JP (2003) Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22:1783–1794PubMedCrossRef
go back to reference Ihaka R, Gentlaman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5:299–314CrossRef Ihaka R, Gentlaman R (1996) R: a language for data analysis and graphics. J Comput Graph Stat 5:299–314CrossRef
go back to reference Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T, Aozasa K (2006) Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 210:75–84PubMedCrossRef Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, Kim YK, Miyoshi Y, Noguchi S, Nishida T, Aozasa K (2006) Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol 210:75–84PubMedCrossRef
go back to reference Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF (2006) Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 14:65–72PubMedCrossRef Jin JS, Chen A, Hsieh DS, Yao CW, Cheng MF, Lin YF (2006) Expression of serine protease matriptase in renal cell carcinoma: correlation of tissue microarray immunohistochemical expression analysis results with clinicopathological parameters. Int J Surg Pathol 14:65–72PubMedCrossRef
go back to reference Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11:5730–5739PubMedCrossRef Jones J, Otu H, Spentzos D, Kolia S, Inan M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, Jonas D, Libermann TA (2005) Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 11:5730–5739PubMedCrossRef
go back to reference Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173:1496–1501PubMedCrossRef Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA (2005) Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173:1496–1501PubMedCrossRef
go back to reference Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11:5128–5139PubMedCrossRef Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G (2005) Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 11:5128–5139PubMedCrossRef
go back to reference Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853–1862PubMedCrossRef Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS (2005) Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 173:1853–1862PubMedCrossRef
go back to reference Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T, Takahashi K, Tomita Y (2006) Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer 95:1244–1249PubMedCrossRef Maruyama R, Yamana K, Itoi T, Hara N, Bilim V, Nishiyama T, Takahashi K, Tomita Y (2006) Absence of Bcl-2 and Fas/CD95/APO-1 predicts the response to immunotherapy in metastatic renal cell carcinoma. Br J Cancer 95:1244–1249PubMedCrossRef
go back to reference Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169:821–827PubMedCrossRef Mejean A, Oudard S, Thiounn N (2003) Prognostic factors of renal cell carcinoma. J Urol 169:821–827PubMedCrossRef
go back to reference Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103–3111PubMedCrossRef Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F, Golanov A, Joos S, Lichter P (2004) Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64:3103–3111PubMedCrossRef
go back to reference Nentwich HA, Mustafa Z, Rugg MS, Marsden BD, Cordell MR, Mahoney DJ, Jenkins SC, Dowling B, Fries E, Milner CM, Loughlin J, Day AJ (2002) A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module. Chromosomal localization, frequency analysis, modeling, and expression. J Biol Chem 277:15354–15362PubMedCrossRef Nentwich HA, Mustafa Z, Rugg MS, Marsden BD, Cordell MR, Mahoney DJ, Jenkins SC, Dowling B, Fries E, Milner CM, Loughlin J, Day AJ (2002) A novel allelic variant of the human TSG-6 gene encoding an amino acid difference in the CUB module. Chromosomal localization, frequency analysis, modeling, and expression. J Biol Chem 277:15354–15362PubMedCrossRef
go back to reference Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20:4402–4408PubMedCrossRef Scherl-Mostageer M, Sommergruber W, Abseher R, Hauptmann R, Ambros P, Schweifer N (2001) Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene 20:4402–4408PubMedCrossRef
go back to reference Shimazui T, Oosterwijk E, Debruyne FM, Schalken JA (1996) Molecular prognostic factor in renal cell carcinoma. Semin Urol Oncol 14:250–255PubMed Shimazui T, Oosterwijk E, Debruyne FM, Schalken JA (1996) Molecular prognostic factor in renal cell carcinoma. Semin Urol Oncol 14:250–255PubMed
go back to reference Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H (2006) Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. Oncol Rep 15:1181–1184PubMed Shimazui T, Kojima T, Onozawa M, Suzuki M, Asano T, Akaza H (2006) Expression profile of N-cadherin differs from other classical cadherins as a prognostic marker in renal cell carcinoma. Oncol Rep 15:1181–1184PubMed
go back to reference Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104:2323–2333PubMedCrossRef Stadler WM (2005) Targeted agents for the treatment of advanced renal cell carcinoma. Cancer 104:2323–2333PubMedCrossRef
go back to reference Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M, Gunawan B, Vingron M, Fuzesi L, Poustka A (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11:646–655PubMed Sultmann H, von Heydebreck A, Huber W, Kuner R, Buness A, Vogt M, Gunawan B, Vingron M, Fuzesi L, Poustka A (2005) Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin Cancer Res 11:646–655PubMed
go back to reference Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98:9754–9759PubMedCrossRef Takahashi M, Rhodes DR, Furge KA, Kanayama H, Kagawa S, Haab BB, Teh BT (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98:9754–9759PubMedCrossRef
go back to reference Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, Merino M, Walther MM, Simon R, Klausner RD, Linehan WM (2003) Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100:6958–6963PubMedCrossRef Vasselli JR, Shih JH, Iyengar SR, Maranchie J, Riss J, Worrell R, Torres-Cabala C, Tabios R, Mariotti A, Stearman R, Merino M, Walther MM, Simon R, Klausner RD, Linehan WM (2003) Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100:6958–6963PubMedCrossRef
go back to reference Yonezawa Y, Nagashima Y, Sato H, Virgona N, Fukumoto K, Shirai S, Hagiwara H, Seki T, Ariga T, Senba H, Suzuki K, Asano R, Hagiwara K, Yano T (2005) Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol Carcinog 43:188–197PubMedCrossRef Yonezawa Y, Nagashima Y, Sato H, Virgona N, Fukumoto K, Shirai S, Hagiwara H, Seki T, Ariga T, Senba H, Suzuki K, Asano R, Hagiwara K, Yano T (2005) Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol Carcinog 43:188–197PubMedCrossRef
Metadata
Title
Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma
Authors
Yasuo Awakura
Eijiro Nakamura
Takeshi Takahashi
Hirokazu Kotani
Yoshiki Mikami
Tadashi Kadowaki
Akira Myoumoto
Hideo Akiyama
Noriyuki Ito
Toshiyuki Kamoto
Toshiaki Manabe
Hitoshi Nobumasa
Gozoh Tsujimoto
Osamu Ogawa
Publication date
01-12-2008
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2008
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-008-0412-4

Other articles of this Issue 12/2008

Journal of Cancer Research and Clinical Oncology 12/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.